A new Power Of Attorney is enclosed. Please direct all future correspondence to customer number 28765.

Respectfully submitted,

Date: 1/23/02

Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN
200 Park Avenue
New York, New York 10166-4193

(212) 294-3311

APPENDIX A

MARKED COPY OF AMENDED CLAIM

17. A CB2 specific [antagonist] agonist comprising a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is (a) -R'N(R")$_2$ wherein R' is C_1-C_5 straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (b) -Q wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) -R'X wherein R' is C_1-C_5 straight or branched chain alkyl and X is halogen, (d) -R'C(O)N(R")$_2$ wherein R' is a direct bond or C_1-C_5 straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C_1-C_5 straight orbranched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (e) -R'C(O)OR" wherein R' is a direct bond or C_1-C_5 straight or branched chain alkyl and R" is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (f) -R' wherein R' is C_1-C_5 straight or branched chain alkyl, or (g) -R'OR"' wherein R' is C_1-C_5 straight or branched chain alkyl and R"' is hydrogen or C_1-C_5 alkyl;

G is hydrogen, halogen, or -OR_2 wherein R_2 is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"', -OC(O)R"', C(O)OR"', or -C(O)R" moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl; and

R_3 is (a) C_1-C_{12} straight or branched chain alkyl, (b) -OR"", in which R"" is a straight chain or branched C_2-C_9 alkyl which rnay be substituted at the terminal carbon atom by a phenyl group, or (c) -$(CH_2)_n$ OR"' wherein n is an integer of 1 to 7 and R"' is hydrogen or C_1-C_5 alkyl.

APPENDIX B

CURRENTLY PENDING CLAIMS

1. A pharmaceutical composition for treating or preventing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune disease, comprising as an active ingredient a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is (a) -R'N(R")$_2$ wherein R' is C_1-C_5 straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (b) -Q wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) -R'X wherein R' is C_1-C_5 straight or branched chain alkyl and X is halogen, (d) -R'C(O)N(R")$_2$ wherein R' is a direct bond or C_1-C_5 straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C_1-C_5 straight orbranched chain alkyl optionally containing a

terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C_1-C_5 straight or branched chain alkyl, (e) -R'C(O)OR'' wherein R' is a direct bond or C_1-C_5 straight or branched chain alkyl and R'' is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C_1-C_5 straight or branched chain alkyl, (f) -R' wherein R' is C_1-C_5 straight or branched chain alkyl, or (g) -R'OR''' wherein R' is C_1-C_5 straight or branched chain alkyl and R''' is hydrogen or C_1-C_5 alkyl;

G is hydrogen, halogen, or $-OR_2$ wherein R_2 is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR''', -OC(O)R''', C(O)OR''', or -C(O)R'' moiety wherein R''' is hydrogen or C_1-C_5 straight or branched chain alkyl; and

R_3 is (a) C_1-C_{12} straight or branched chain alkyl, (b) -OR'''', in which R'''' is a straight chain or branched C_2-C_9 alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) $-(CH_2)_n$ OR''' wherein n is an integer of 1 to 7 and R''' is hydrogen or C_1-C_5 alkyl.

2. The compound of claim 1 wherein, R_3 is a straight chain or branched chain $-C_5$-C_{12} alkyl.

3. The compound of claim 1, wherein R_3 is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

4. The compound of claim 1, wherein R_1 is $-CH_2OH$, G is $-OCH_3$, and R_3 is 1,1-dimethyl heptyl.

5. The compound of claim 1, wherein R_1 is $-CH_2OH$, $C(O)N(R'')_2$, -C(O)OR'', -COOH, an amino acid, or a carboxamide.

6. A pharmaceutical composition for treating, preventing, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of a compound of claim 1.

7. A pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable diluent or carrier.

8. The pharmaceutical composition of claim 7, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.

17. A CB2 specific agonist comprising a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is (a) -R'N(R")$_2$ wherein R' is C_1-C_5 straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (b) -Q wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) -R'X wherein R' is C_1-C_5 straight or branched chain alkyl and X is halogen, (d) -R'C(O)N(R")$_2$ wherein R' is a direct bond or C_1-C_5 straight or branched chain alkyl and each R", which may be the same or different, is hydrogen or C_1-C_5 straight orbranched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (e) -R'C(O)OR" wherein R' is a direct bond or C_1-C_5 straight or branched chain alkyl and R" is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"' or -OC(O)R"' moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl, (f) -R' wherein R' is C_1-C_5 straight or branched chain alkyl, or (g) -R'OR"' wherein R' is C_1-C_5 straight or branched chain alkyl and R"' is hydrogen or C_1-C_5 alkyl;

G is hydrogen, halogen, or -OR_2 wherein R_2 is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal -OR"', -OC(O)R"', C(O)OR"', or -C(O)R" moiety wherein R"' is hydrogen or C_1-C_5 straight or branched chain alkyl; and

R_3 is (a) C_1-C_{12} straight or branched chain alkyl, (b) -OR"", in which R"" is a straight chain or branched C_2-C_9 alkyl which rnay be substituted at the terminal carbon atom by a phenyl group, or (c) -$(CH_2)_n$ OR"' wherein n is an integer of 1 to 7 and R"' is hydrogen or C_1-C_5 alkyl.